340B Under Siege: Lilly, CMS, and States All Move at Once
Supply Chain Pulse — 2026-07-03
Eli Lilly has halted 340B discounts and the hospital sector is demanding federal intervention — a significant escalation that threatens drug acquisition costs for safety-net facilities that rely on the program to cross-subsidize care. It lands the same week CMS proposed cutting 340B pharmaceutical reimbursements further in its CY2027 OPPS rule, and while states scramble to fill the federal policy vacuum with their own contract pharmacy and PBM regulations. Three separate forces are reshaping 340B simultaneously, and if you're a supply chain leader whose formulary strategy depends on program savings, the window for assuming stability is closing fast.
Quick Hits
- CMS CY2027 OPPS/ASC Proposed Rule Fact Sheet: Full details on payment rates, 340B policy, and ASC-covered procedures now available directly from CMS. (CMS Newsroom)
- UC San Diego Health and Palomar Health are forming a combined system — a merger that will consolidate supply chain contracts, GPO leverage, and distribution networks across two major San Diego-area operators. (Modern Healthcare)
Lilly Halts 340B Drug Discounts, Triggers Fury
Eli Lilly has stopped honoring 340B discounts, prompting hospitals to call on federal authorities to intervene and force compliance. For supply chain and pharmacy leaders, this is a direct hit to drug acquisition cost models — particularly for high-cost Lilly products like tirzepatide and insulin — at facilities that depend on 340B savings to fund uncompensated care. Watch for other manufacturers to test the same move if federal enforcement remains tepid.
CMS Proposes 2.4% Hospital Outpatient Pay Bump, 340B Cuts
The CY2027 OPPS proposed rule offers a 2.4% payment update for hospital outpatient departments but pairs it with significant reductions to 340B drug reimbursements — a double pressure on margins for covered entities already reeling from Lilly's pullout. ASC leaders should note that the companion ASC payment rule is also in the proposal and will affect procedure-level reimbursement planning. Comments are due before the rule finalizes this fall, and now is the time to model the impact.
How States Are Filling the 340B Policy Vacuum
With federal oversight of 340B in flux, at least a dozen states are enacting their own rules governing contract pharmacies, transparency requirements, and PBM practices — creating a patchwork compliance landscape for multi-state health systems. Supply chain and pharmacy teams operating across state lines now face the prospect of managing materially different 340B program rules by geography. This is no longer just a federal policy watch item; it requires state-by-state legal and operational mapping.
UPS Announces $48 Million Investment in Temperature-Controlled Facilities
UPS is pumping $48 million into cold-chain transfer facilities designed to maintain temperature integrity during handoffs between air and ground transport — a critical vulnerability point for biologics, vaccines, and specialty pharmaceuticals. For supply chain managers sourcing temperature-sensitive products, expanded UPS cold-chain capacity could mean more routing flexibility and reduced excursion risk on inbound shipments. This investment signals growing logistics-sector confidence in sustained specialty drug volume growth.
Source: Healthcare Purchasing News
Innovating Healthcare Resilience: The U.S. Digital Stockpile Challenge
A federal competition is underway to build a secure, distributed network of manufacturers and digital repositories capable of rapidly producing essential healthcare products during national emergencies — think a virtual strategic national stockpile with on-demand manufacturing triggers. For hospital supply chain leaders who lived through PPE shortages in 2020, this initiative represents the most serious structural attempt yet to prevent a repeat. The practical payoff is years away, but understanding which manufacturers are participating could matter for future sourcing relationships.
Source: Healthcare Purchasing News
How Outpatient Surgery Is Opening the Door for Robot Makers
Distalmotion CEO Greg Roche says the accelerating shift of procedures to ASCs is a direct growth driver for his robotic surgery platform — because ASC-optimized robotic systems can be smaller, simpler, and cheaper than hospital-grade surgical robots. For ASC supply chain and capital equipment teams, this trend means more vendors are entering the robotic surgery space with ASC-first designs, expanding negotiating leverage and competitive options. Expect procurement complexity to rise alongside the vendor count.
US Blocks Quick USMCA Extension, Putting Annual Review Process Into Motion
The U.S. has rejected a fast-track extension of the USMCA trade agreement, triggering an annual review process — meaning tariff terms with Mexico and Canada remain uncertain on a rolling basis through at least 2036. For healthcare supply chains sourcing medical devices, raw materials, or finished goods from either country, this keeps procurement teams in a prolonged planning limbo that makes multi-year supplier contracts harder to structure. Model your Mexico and Canada exposure now; this uncertainty isn't resolving quickly.
Source: Supply Chain Dive - Healthcare
How Hospitals Are Outpacing Rivals in Outpatient Push
Health systems are aggressively expanding outpatient surgery, imaging, infusion, and rehab capacity as payers and regulators push volume out of inpatient settings — and in doing so, pulling ahead of private equity-backed competitors for market share. For supply chain leaders, this shift means procurement portfolios must flex to support a broader range of lower-acuity, high-volume outpatient settings with different par levels, space constraints, and delivery cadences than traditional inpatient units. The outpatient build-out isn't coming — it's already reshaping what you buy and where you stock it.
You're receiving this because you subscribed to Supply Chain Pulse, a daily brief for healthcare supply chain professionals. Unsubscribe